---
title: "RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298666909.md"
description: "In a report released on September 9, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $123.00. The company’s shares closed yesterday at $145.65. Abrahams covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, Biogen, and Regeneron. According to TipRanks, Abrahams has an average return of 13.5% and a 54.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.11 average price target."
datetime: "2026-09-11T01:45:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298666909.md)
  - [en](https://longbridge.com/en/news/298666909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298666909.md)
generator: "portal-rs"
---

# RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

In a report released on September 9, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $123.00. The company’s shares closed yesterday at $145.65.

Abrahams covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, Biogen, and Regeneron. According to TipRanks, Abrahams has an average return of 13.5% and a 54.11% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $159.11 average price target.

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth](https://longbridge.com/en/news/298621247.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing](https://longbridge.com/en/news/298400767.md)
- [Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology](https://longbridge.com/en/news/298815400.md)
- [Trump Is Still Very Much Operating Off ‘Concepts’ Of A Health Care Plan](https://longbridge.com/en/news/298872418.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**